Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and the current price. RP1 demonstrates real antitumor activity and durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results